Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective

Paper proposes treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (i.e. 0, A, B, & C), specifically in relation to surgery, locoregional therapies, and systemic therapy. It also suggests strategies to modify risk during pandemic.


Lancet Gastroenterology and Hepatology